Wegovy, also known as Ozempic when marketed in lower doses, is a weight-loss drug that is already making headlines globally, and now as of the 1st of July, it’s available for prescription in Aotearoa.

Given that New Zealand is currently ranked 31st in the world for obesity rates, according to The World Obesity Federation, some experts believe Wegovy could have a major impact on obesity levels nationwide. Especially if it were to become publicly funded.

To talk about why the drug isn’t publicly funded at the moment, and what kind of impact Wegovy could have on obesity in Aotearoa, Producer Max spoke with Boyd Swinburn, Professor of Population, Nutrition and Global Health at the University of Auckland.